REGN REGN5713-5715
Alternative Names: REGN-5713-5715Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antiallergics; Antibodies; Tree pollen allergy immunotherapies
- Mechanism of Action IgE receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Allergic conjunctivitis
Most Recent Events
- 19 Nov 2024 Phase-III clinical trials in Allergic conjunctivitis in Canada, USA (Parenteral) (NCT06602739)
- 01 Oct 2024 Preclinical trials in Allergic conjunctivitis in USA (Parenteral) before October 2024
- 01 Oct 2024 Regeneron Pharmaceuticals plans a phase III trial for Allergic conjunctivitis in October 2024 (NCT06602739)